The IES study (A5991012) investigated 4742 patients treated for 2 to 3 years with tamoxifen, who either continued the same treatment or switched to Aromasin® for a total treatment period of 5 years. Only 65 Romanian patients were enrolled in the IES study. It would therefore appear to be essential to evaluate and confirm the tolerability of Aromasin® and the ways in which it is used on a broader sample of patients and under the standard conditions of use as stipulated in the MA. This Non-Interventional study was designed to address these issues.
This is a prospective, non-comparative, non interventional study (NIS) in four hundred (400) postmenopausal women hormone-receptor positive invasive with early breast cancer, following 2-3 years of initial adjuvant tamoxifen therapy conducted in 60 sites from Romania according to protocol A5991091.The selection of patients based on diagnosis, the attribution of medicinal products and the follow-up of the subjects fall within the current medical practice. A Non-Interventional study is primarily observational in nature. The present Non-interventional Study is performed by medical oncologist and medical oncologist /radiation oncologist who agree to take part in this project. n/a The study was prematurely terminated on August 31th 2012 due to unexpected high rate of patient withdrawal caused by Aromasin reimbursement policy change in Romania; There were no safety issues related to study termination.
Study Type
OBSERVATIONAL
Enrollment
378
25 mg daily continuously
Number of Participants With Treatment-Emergent Adverse Events (AEs) by Severity
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs were graded using National Cancer Institute (NCI)/Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events version 4.0 (CTCAE,v4.0) as Grade 1 (Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated); Grade 2 (Moderate; minimal, local or noninvasive intervention; limiting age-appropriate instrumental activities of daily living \[ADL\]); Grade 3 (Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization; disabling; limiting self-care ADL); Grade 4 (Life-threatening; urgent intervention indicated) and Grade 5 (Death related to AE).
Time frame: Baseline up to 28 days after last dose
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) by Relationship to Study Drug
An AE (all causalities) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to exemestane was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.
Time frame: Baseline up to 28 days after last dose
Number of Missed Exemestane Doses
Time frame: Week 25, 49, 73, 97, 121, 145
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Policlinica Judeteana 1 Pitesti - Cabinet oncologie
Piteşti, Argeş, Romania
Spitalul Judetean de Urgenta Bacau
Bacau, Bacău, Romania
CMDT MAPN Washington Ambulator oncologie
Bucharest, București, Romania
Centru D.T. Titan Cabinet oncologie
Bucharest, București, Romania
Spitalul Judetean de Urgenta Resita Sectia oncologie medicala
Reşiţa, Caraș-Severin County, Romania
Institutul Oncologic "Prof. Dr. Ion Chiricuta" Cluj Napoca
Cluj-Napoca, Cluj, Romania
Spitalul Clinic Judetean de Urgenta Cluj, Clinica de Oncologie Medicala si Radioterapie
Cluj-Napoca, Cluj, Romania
Spitalul Judetean Covasna, Sectia Oncologie medicala
Sfântu Gheorghe, Covasna, Romania
Spitalul Judetean de Urgenta Targoviste
Târgovişte, Dâmbovița County, Romania
Spitalulul Judetean de Urgenta Deva, Ambulator oncologie medicala
Hunedoara, Hunedoara County, Romania
...and 30 more locations
Number of Participants With Reasons for Discontinuing Exemestane Therapy
Time frame: Baseline up to Year 3
Number of Participants Who Received Hormonal Therapy or Chemotherapy After Discontinuation of Exemestane Therapy
Time frame: Baseline up to Year 3
Percentage of Participants Who Discontinued the Exemestane Therapy
Time frame: Baseline up to Year 3
Recurrence-free Survival (RFS)
Recurrence-free survival defined as the time from study inclusion to the first date of documented recurrence, with events defined as: local recurrence, distant recurrence, new primary breast cancer (includes both ipsilateral and contralateral second primaries), or death due to any cause. New primary cancer at sites other than the breast were not considered as recurrence.
Time frame: Baseline up to Year 3
Time to Disease Progression (TTP)
Time to disease progression was defined as the time from inclusion to first local or distant recurrence at any site.
Time frame: Baseline up to Year 3